Literature DB >> 197008

Immune response and latent infection after topical treatment of herpes simplex virus infection in hairless mice.

R J Klein, A E Friedman-Kien, A A Fondak, E Buimovici-Klein.   

Abstract

Treatment of herpes simplex virus (HSV)-infected hairless mice with a 2% phosphonoacetic acid (PAA) ointment prevented the appearance of virus-induced skin lesions and subsequent central nervous system (CNS) involvement. Treatment started 24 h after infection significantly reduced the intensity of the skin lesions and also prevented CNS involvement. After four to six applications of PAA ointment, a moderate skin erythemia developed, followed by scaling and complete healing 7 days after cessation of the treatment. Mice treated early after HSV infection had low or undetectable levels of virus-specific antibodies but were completely resistant to reinfection. Early treatment prevented the development of a latent ganglionic infection, but treatment initiated 24 h after infection could not prevent the establishment of the latent infection. PAA-treated and HSV-infected mice with nondetectable levels of antibodies did not develop, with a single exception, a latent ganglionic infection unpon reinfection. The cell-mediated immune response determined by levels of [14C]thymidine incorporation in Ficoll-Hypaque-purified spleen lymphocytes cultures was low in PAA-treated mice; it increased slightly after challenge infection but was strong in mice that proved to harbor a latent HSV infection in the ganglia.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 197008      PMCID: PMC421039          DOI: 10.1128/iai.16.3.842-848.1977

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  29 in total

1.  Latent infection of sensory ganglia with herpes simplex virus: efficacy of immunization.

Authors:  R W Price; M A Walz; C Wohlenberg; A L Notkins
Journal:  Science       Date:  1975-05-30       Impact factor: 47.728

2.  Isolation of herpes simplex virus clones and drug resistant mutants in microcultures.

Authors:  R J Klein
Journal:  Arch Virol       Date:  1975       Impact factor: 2.574

3.  Inhibition of Epstein-Barr virus DNA synthesis and late gene expression by phosphonoacetic acid.

Authors:  W C Summers; G Klein
Journal:  J Virol       Date:  1976-04       Impact factor: 5.103

4.  Effect of phosphonoacetate on Marek's disease virus replication.

Authors:  L F Lee; K Nazerian; S S Leinbach; J M Reno; J A Boezi
Journal:  J Natl Cancer Inst       Date:  1976-04       Impact factor: 13.506

5.  Phosphonoacetic acid-resistant herpes simplex virus infection in hairless mice.

Authors:  R J Klein; A E Friedman-Kien
Journal:  Antimicrob Agents Chemother       Date:  1975-03       Impact factor: 5.191

6.  Synthesis of herpes simplex virus, vaccinia virus, and adenovirus DNA in isolated HeLa cell nuclei. I. Effect of viral-specific antisera and phosphonoacetic acid.

Authors:  A Bolden; J Aucker; A Weissbach
Journal:  J Virol       Date:  1975-12       Impact factor: 5.103

7.  Mutants of herpes simplex virus types 1 and 2 that are resistant to phosphonoacetic acid induce altered DNA polymerase activities in infected cells.

Authors:  J Hay; J H Subak-Sharpe
Journal:  J Gen Virol       Date:  1976-04       Impact factor: 3.891

8.  Human cytomegalovirus. IV. Specific inhibition of virus-induced DNA polymerase activity and viral DNA replication by phosphonoacetic acid.

Authors:  E S Huang
Journal:  J Virol       Date:  1975-12       Impact factor: 5.103

9.  Mode of inhibition of herpes simplex virus DNA polymerase by phosphonoacetate.

Authors:  J C Mao; E E Robishaw
Journal:  Biochemistry       Date:  1975-12-16       Impact factor: 3.162

10.  Mechanism of phosphonoacetate inhibition of herpesvirus-induced DNA polymerase.

Authors:  S S Leinbach; J M Reno; L F Lee; A F Isbell; J A Boezi
Journal:  Biochemistry       Date:  1976-01-27       Impact factor: 3.162

View more
  15 in total

1.  Latent herpes simplex virus in ganglia of mice after primary infection and reinoculation at a distant site.

Authors:  R J Klein; A E Friedman-Kien; E Brady
Journal:  Arch Virol       Date:  1978       Impact factor: 2.574

2.  Orofacial herpes simplex virus infection in hairless mice: latent virus in trigeminal ganglia after topical antiviral treatment.

Authors:  R J Klein; A E Friedman-Kien; P B Yellin
Journal:  Infect Immun       Date:  1978-04       Impact factor: 3.441

3.  Latent herpes simplex virus infections in sensory ganglia of mice after topical treatment with adenine arabinoside and adenine arabinoside monophosphate.

Authors:  R J Klein; A E Friedman-Kien
Journal:  Antimicrob Agents Chemother       Date:  1977-11       Impact factor: 5.191

4.  Therapeutic effect of trisodium phosphonoformate on cutaneous herpesvirus infection in guinea pigs.

Authors:  S Alenius; Z Dinter; B Oberg
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

5.  Neutralising antibody in mice with primary and recurrent herpes simplex virus infection.

Authors:  J M Darville; W A Blyth
Journal:  Arch Virol       Date:  1982       Impact factor: 2.574

6.  Topical treatment of cutaneous herpes simplex virus infection in hairless mice with (E)-5-(2-bromovinyl)-2'-deoxyuridine and related compounds.

Authors:  E de Clercq
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

7.  Latent infections of sensory ganglia as influenced by phosphonoformate treatment of herpes simplex virus-induced skin infections in hairless mice.

Authors:  R J Klein; E DeStefano; E Brady; A E Friedman-Kien
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

8.  Latent herpes simplex virus infections in sensory ganglia of hairless mice prevented by acycloguanosine.

Authors:  R J Klein; A E Friedman-Kien; E DeStefano
Journal:  Antimicrob Agents Chemother       Date:  1979-05       Impact factor: 5.191

9.  Experimental skin infection with an acyclovir resistant herpes simplex virus mutant: response to antiviral treatment and protection against reinfection.

Authors:  R J Klein; E DeStefano; E Brady; A E Friedman-Kien
Journal:  Arch Virol       Date:  1980       Impact factor: 2.574

10.  In vitro and in vivo inhibition of myxoma virus by treatment with phosphonoacetic acid.

Authors:  J M Goodrich; K W Lee; H C Hinze
Journal:  Arch Virol       Date:  1981       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.